

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: CSFB2/22 - Cerebrospinal Fluid Analysis

Deadline: 28.11.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(330) Total protein</b>					99						99	96	97%	
Samples and groups	[mg/L]													
<b>Sample A</b>		284	41	14	99	CVP	284	10,0	27%	207	361	99	96	97%
(1) Abbott		263	16	6,1	12	0						12		
(58) Beckman Coulter (AU)		322	15	4,6	15	0						15		
(60) Roche		260	14	5,4	43	0						43		
(162) Siemens (Atellica)		341	14	4,1	8	0						8		
Other					21	0						21		
							2x 46, 1x 49, 1x 75, 4x 77, 1x 85, 1x 115, 3x 149, 1x 158, 1x 166, 1x 178, 4x 179, 1x 998					99	99	100%
<b>Sample B</b>		625	50	8,0	99	CVP	625	12	27%	456	794	99	99	100%
(1) Abbott		616	25	4,0	12	0						12		
(58) Beckman Coulter (AU)		679	21	3,1	15	0						15		
(60) Roche		591	24	4,0	43	0						43		
(162) Siemens (Atellica)		681	17	2,5	8	0						8		
Other					21	0						21		
							2x 46, 1x 49, 1x 75, 4x 77, 1x 85, 1x 115, 3x 149, 1x 158, 1x 166, 1x 178, 4x 179, 1x 998							
<b>(331) Glucose</b>					99							99	98	99%
Samples and groups	[mmol/L]													
<b>Sample A</b>		3,36	0,089	2,7	99	CVP	3,36	0,022	18%	2,75	3,97	99	98	99%
(1) Abbott		3,32	0,11	3,3	10	0						10		
(46) Erba Lachema		3,36	0,089	2,6	7	0						7		
(58) Beckman Coulter (AU)		3,43	0,095	2,8	17	0						17		
(60) Roche		3,36	0,07	2,1	42	0						42		
(162) Siemens (Atellica)		3,32	0,12	3,6	9	0						9		
Other					14	0						14		
							1x 5, 2x 49, 3x 149, 2x 158, 4x 179, 1x 187, 1x 188							
<b>Sample B</b>		2,12	0,067	3,1	99	CVP	2,12	0,016	18%	1,73	2,51	99	99	100%
(1) Abbott		2,10	0,085	4,1	10	0						10		
(46) Erba Lachema		2,13	0,10	4,9	7	0						7		
(58) Beckman Coulter (AU)		2,14	0,053	2,5	17	0						17		
(60) Roche		2,12	0,053	2,5	42	0						42		
(162) Siemens (Atellica)		2,11	0,03	1,4	9	0						9		
Other					14	0						14		
							1x 5, 2x 49, 3x 149, 2x 158, 4x 179, 1x 187, 1x 188							
<b>(333) Albumin</b>					75							75	73	97%
Samples and groups	[mg/L]													
<b>Sample A</b>		184	13	7,3	75	CVP	184	3,8	23%	141	227	75	74	99%
(1) Abbott		196	5,5	2,8	7	0						7		
(12) Beckman Coulter		183	3,7	2,0	5	0						5		
(58) Beckman Coulter (AU)		183	13	7,2	8	0						8		
(60) Roche		179	5,7	3,2	24	0						24		
(149) Siemens (Dade, BN, Dimension)		196	16	8,4	11	0						11		
(162) Siemens (Atellica)		180	29	16	5	0						5		
(179) Siemens		181	13	7,0	7	0						7		
Other					8	0						8		
							1x 28, 1x 49, 1x 75, 3x 91, 1x 152, 1x 999							
<b>Sample B</b>		412	29	6,9	75	CVP	412	8,1	23%	317	507	75	74	99%
(1) Abbott		445	8,2	1,8	7	0						7		
(12) Beckman Coulter		423	10	2,5	5	0						5		
(58) Beckman Coulter (AU)		410	13	3,1	8	0						8		
(60) Roche		403	18	4,4	24	0						24		
(149) Siemens (Dade, BN, Dimension)		430	31	7,3	11	0						11		
(162) Siemens (Atellica)		401	62	15	5	0						5		
(179) Siemens		397	37	9,3	7	0						7		
Other					8	0						8		
							1x 28, 1x 49, 1x 75, 3x 91, 1x 152, 1x 999							
<b>(334) IgG</b>					46							46	45	98%
Samples and groups	[mg/L]													
<b>Sample A</b>		31,0	2,9	9,2	46	CVP	31	1,0	24%	23,5	38,5	46	45	98%
(12) Beckman Coulter		31,8	1,3	4,0	6	0						6		
(60) Roche		28,5	1,5	5,3	14	0						14		
(91) Binding Site		34,5	1,2	3,4	6	0						6		
(149) Siemens (Dade, BN, Dimension)		32,5	2,4	7,3	11	0						11		
Other					9	0						9		
							1x 28, 2x 58, 2x 162, 4x 179							
<b>Sample B</b>		73,3	4,3	5,9	46	CVP	73,3	1,6	24%	55,7	90,9	46	46	100%
(12) Beckman Coulter		76,1	2,4	3,2	6	0						6		

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: CSFB2/22 - Cerebrospinal Fluid Analysis

Deadline: 28.11.2022

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(334) IgG</b>					46							46	45	98%
Samples and groups	[mg/L]													
<b>Sample B</b>		73,3	4,3	5,9	46	CVP	73,3	1,6	24%	55,7	90,9	46	46	100%
(60) Roche		70,9	2,2	3,1	14	0						14		
(91) Binding Site		77,8	4,7	6,0	6	0						6		
(149) Siemens (Dade, BN, Dimension)		72,2	3,7	5,2	11	0						11		
Other					9	0						9		
							1x 28, 2x 58, 2x 162, 4x 179							
<b>(335) IgA</b>					20							20	18	90%
Samples and groups	[mg/L]													
<b>Sample A</b>		4,95	0,51	10	20	CVP	4,95	0,28	32%	3,36	6,54	20	18	90%
(149) Siemens (Dade, BN, Dimension)		4,76	0,53	11	10	0						10		
Other					10	0						10		
							2x 12, 1x 58, 4x 91, 3x 179							
<b>Sample B</b>		8,75	1,0	11	20	CVP	8,75	0,55	32%	5,95	11,6	20	19	95%
(149) Siemens (Dade, BN, Dimension)		8,36	0,77	9,3	10	0						10		
Other					10	0						10		
							2x 12, 1x 58, 4x 91, 3x 179							
<b>(336) IgM</b>					30							30	29	97%
Samples and groups	[mg/L]													
<b>Sample A</b>		1,65	0,22	13	30	CVP	1,65	0,097	31%	1,13	2,17	30	29	97%
(91) Binding Site		1,51	0,14	9,0	6	0						6		
(149) Siemens (Dade, BN, Dimension)		1,73	0,17	9,5	11	0						11		
Other					13	0						13		
							4x 12, 1x 58, 4x 60, 1x 162, 3x 179							
<b>Sample B</b>		50,1	5,8	12	30	CVP	50,1	2,6	31%	34,5	65,7	30	30	100%
(91) Binding Site		44,5	4,6	10	6	0						6		
(149) Siemens (Dade, BN, Dimension)		54,2	5,0	9,2	11	0						11		
Other					13	0						13		
							4x 12, 1x 58, 4x 60, 1x 162, 3x 179							
<b>(338) Lactate</b>					96							96	92	96%
Samples and groups	[mmol/L]													
<b>Sample A</b>		1,94	0,096	4,9	96	CVP	1,94	0,024	20%	1,55	2,33	96	93	97%
(1) Abbott		2,04	0,052	2,6	8	0						8		
(49) BioVendor		1,84	0,059	3,2	5	0						5		
(58) Beckman Coulter (AU)		1,91	0,075	3,9	15	0						15		
(60) Roche		1,97	0,051	2,6	44	0						44		
(162) Siemens (Atellica)		1,79	0,059	3,3	9	0						9		
Other					15	0						15		
							1x 61, 2x 75, 1x 116, 3x 149, 1x 178, 4x 179, 1x 187, 2x 188							
<b>Sample B</b>		8,04	0,41	5,2	96	CVP	8,04	0,10	20%	6,43	9,65	96	95	99%
(1) Abbott		8,31	1,1	13	8	0						8		
(49) BioVendor		7,74	0,20	2,6	5	0						5		
(58) Beckman Coulter (AU)		8,13	0,29	3,5	15	0						15		
(60) Roche		8,07	0,19	2,4	44	0						44		
(162) Siemens (Atellica)		7,25	0,11	1,5	9	0						9		
Other					15	0						15		
							1x 61, 2x 75, 1x 116, 3x 149, 1x 178, 4x 179, 1x 187, 2x 188							

st\_kn\_p

End of report

Printed: 05.12.2022